Acadia Pharmaceuticals EV/EBIT ACAD

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.

Today, Oct 23, 2026: 29.1×
2-year median: 21.0×
Against its 2-year history: 67th; percentile: 0 is its lowest day, 100 its highest
2-year range: 7.5× to 101×
Peer median: 16.4×

Acadia Pharmaceuticals' EV/EBIT is 29.1× as of Oct 23, 2026.

That is above its 2-year median of 21.0×, higher than on 67% of days in the last 2 years.

Over that time it ranged from 7.5× in Apr 2025 to 101× in Aug 2024.

The median for 10 large drugmakers of a similar size is 16.4×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	29.1×	12.2×	48.6×
2025	16.1×	7.5×	25.1×
2024	20.5×	19.6×	101×

Against its peers

Companies in Drug Manufacturers - General nearest Acadia Pharmaceuticals' size, closest first, today.

Company	EV/EBIT
ACADAcadia Pharmaceuticals	29.1×
OGNOrganon	9.5×
LQDALiquidia	21.7×
ARQTArcutis Biotherapeutics	111×
INDVIndivior Pharmaceuticals	7.8×
NRIXNurix Therapeutics	7.1×
PBHPrestige Consumer Healthcare	14.5×
HRMYHarmony Biosciences	6.9×
KNSAKiniksa Pharmaceuticals International	54.6×
LGNDLigand Pharmaceuticals	57.7×
AMRXAmneal Pharmaceuticals	18.3×
Peer median	16.4×

Where Acadia Pharmaceuticals ranks

#39of 48Large drugmakers with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Acadia Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.